Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. [PubChem] (en)
|
http://linked.open...gy/drugbank/group
| - approved (en)
- withdrawn (en)
|
http://linked.open...drugbank/halfLife
| - The mean serum half-life is 1.5 hours. Half-life in patients with impaired renal function may exceed 10 hours. (en)
|
http://linked.open...ugbank/indication
| - For the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Proteus vulgaris</i>, <i>Klebsiella</i> species (including <i>K. pneumoniae</i>), and <i>Enterobacter</i> species. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Evidence exists that cinoxacin binds strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis. It appears to also inhibit DNA gyrase. This enzyme is necessary for proper replicated DNA separation. By inhibiting this enzyme, DNA replication and cell division is inhibited. (en)
|
http://linked.open.../drugbank/synonym
| - Cinoxacin (en)
- 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid (en)
- Cinoxacine (en)
- Cinoxacino (en)
- Cinoxacinum (en)
- 5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid (en)
|
http://linked.open...drugbank/toxicity
| - Oral, subcutaneous, and intravenous LD<sub>50</sub> in the rat is 3610 mg/kg, 1380 mg/kg, and 860 mg/kg, respectively. Oral, subcutaneous, and intravenous LD<sub>50</sub> in the mouse is 2330 mg/kg, 900 mg/kg, and 850 mg/kg, respectively.Symptoms following an overdose of cinoxacin may include anorexia, nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose related. Headache, dizziness, insomnia, photophobia, tinnitus, and a tingling sensation have been reported in some patients. (en)
|
http://linked.open...nk/proteinBinding
| |
http://linked.open...ynthesisReference
| - White, W.A.; U.S. Patent 3,669,965; June 13, 1972; assigned to Eli Lilly & Company. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Rapidly absorbed after oral administration. The presence of food delays absorption but does does not affect total absorption. (en)
|
http://linked.open.../affectedOrganism
| - Enteric bacteria and other eubacteria (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |